HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: C600003-JLR200v1 47/5/892    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Massiello, A. Articles by Chalfant, C. E. Search for Related Content PubMed PubMed Citation Articles by Massiello, A. Articles by Chalfant, C. E. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 47, 892-897, May 2006
Copyright © 2006 by American Society for Biochemistry and Molecular Biology

Short Communication

SRp30a (ASF/SF2) regulates the alternative splicing of caspase-9 pre-mRNA and is required for ceramide-responsiveness

Autumn Massiello^* and Charles E. Chalfant^1,*,

^* Department of Biochemistry, Virginia Commonwealth University, Richmond, VA 23298
Research and Development, Hunter Homes McGuire Veterans Administration Medical Center, Richmond, VA 23249

Published, JLR Papers in Press, February 27, 2006.

¹ To whom correspondence should be addressed. e-mail: cechalfant{at}vcu.edu

ABSTRACT

Two splice variants are derived from the caspase-9 gene, proapoptotic caspase-9a and antiapoptotic caspase-9b, by either the inclusion or exclusion of an exon 3, 4, 5, and 6 cassette. Previous studies from our laboratory have shown that the alternative splicing of caspase-9 and the phosphorylation status of SR proteins, a conserved family of splicing factors, are regulated by chemotherapy and ceramide via the action of protein phosphatase-1. In this study, a link between ceramide, SR proteins, and the alternative splicing of caspase-9 was established. The downregulation of SRp30a in A549 cells by RNA interference technology resulted in an increase in the caspase-9b splice variant, with a concomitant decrease in the caspase-9a splice variant, thereby significantly decreasing the caspase-9a/9b ratio from 1.67 ± 0.11 to 0.56 ± 0.08 (P < 0.005). The specific downregulation of SRp30a also inhibited the ability of exogenous ceramide treatment to induce the inclusion of the exon 3, 4, 5, and 6 cassette. Therefore, we have identified SRp30a as an RNA trans-acting factor that functions as a major regulator of caspase-9 pre-mRNA processing and is required for ceramide to mediate the alternative splicing of caspase-9.

Supplementary key words RNA cis-element • RNA trans-acting factor • A549 cells

Abbreviations: Apaf-1, apoptotic protease activating factor-1; PP1, protein phosphatase-1; RNAi, RNA interference; siRNA, silencer RNA

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. E. Senkal, S. Ponnusamy, M. J. Rossi, J. Bialewski, D. Sinha, J. C. Jiang, S. M. Jazwinski, Y. A. Hannun, and B. Ogretmen Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas Mol. Cancer Ther., February 1, 2007; 6(2): 712 - 722. [Abstract] [Full Text] [PDF]